In the News Archive

  • NYTimes Letter to the Editor: Drug Shortages Continue to Vex Doctors
    February 11, 2014 | New York Times 
  • Outlook 2014: Capitol Commotion
    December 1, 2013 | Medical Marketing and Media 
  • States copying market-based Medicare plan
  • August 14, 2013 | The Philadelphia Inquirer 
  • Medicare Budget Cuts Could Threaten Cancer Patients' Access To Drug Treatments
    August 2, 2013 | Forbes 
  • Government must avoid change in Medicare Part D
    July 1, 2013 | Sun Sentinel 
  • The Wrong Way to Dispose of Drugs
    May 24, 2013 | The Huffington Post 
  • A Hammer in Search of a Nail
    May 24, 2013 | The Burrill Report 
  • A common-sense cut to health care spending
    May 6, 2013 | AL 
  • When generics win, patients lose
    May 1, 2013 | Washington Times 
  • Liberals still going after Medicare drug benefit
    April 8, 2013 | Sun Sentinel 
  • Novartis verdict fallout: Patents vs patients?
    April 6, 2013 | NDTV 
  • Indian drugs will now face backlash, warn analysts in US after Novartis ruling
    April 3, 2013 | NDTV 
  • Obama's fiscal cliff drug 'reform' idea will backfire
  • December 20, 2012 | The Washington Examiner 
  • Experts stress need for innovation in healthcare
    November 28, 2012 | Gulf News 
  • Mirror, Mirror
    November 16, 2012 | The Burrill Report 
  • Biosimilars: The Precarious Struggle Between Cost-driven Health Care Policy and Patient-centered Care
    September 30, 2012 | Washington Policy Center
  • An Ugly Way To Get Insurance
    September 19, 2012 | New York Post
  • Measuring Responsibility in Big Pharma
    September 7, 2012 | Pharmaceutical Executive
  • Protecting Sustainable Innovation
    August 31, 2012 | The Burrill Report
  • The Evolution of Health Care
  • June 29, 2012 | The Chicago Tribune
  • Two ideas on how to save Medicare
  • June 19, 2012 | Washington Examiner
  • Contraception, who cares?
    June 18, 2012 | MedAd News
  • A Gentleman’s D for Mitt
    June 15, 2012 | The Burrill Report
  • Da Bomb
    June 7, 2012 | The Burrill Report
  • Getting Back on Track (and Trace)
    June 1, 2012 | The Burrill Report
  • Living in a Post-IPAB World
    May 30, 2012 | The Riverdale Press
  • Another deadly taste of ObamaCare
    May 29, 2012 | New York Post
  • Animal health and human health are inextricably linked
  • May 15, 2012 | The Hill
  • Drug Shortages and the Role of the Middle Man
    April 13, 2012 | The Burrill Report
  • Obamacare's Medical Mercenaries
    April 13, 2012 | The American Spectator
  • Positive Signals from Washington
    April 13, 2012 | Nature Biotechnology
  • Affordable Care Act Isn't
    April 7, 2012 | The Boston Herald
  • Obama's Broken Promise to Wounded Warriors
    March 27, 2012 | The American Spectator
  • Drugs of Choice
    March 23, 2012 | The Washington Times
  • Sunday Dialogue: Equitable Health Care
    March 23, 2012 | New York Times
  • Time to bid adieu to Obamacare's IPAB
    March 15, 2012 | The Washington Examiner
  • Joint Custody
    March 2, 2012 | The Burrill Report
  • Republicans Rock the Airwaves
    February 24, 2012 | The American Spectator
  • Obama's Nurse Ratched
    February 16, 2012 | The American Spectator
  • Cancer Patients Fume Over Counterfeit Avastin
  • February 15, 2012 | ABC News
  • America needs more breakthrough 'progressive' medicines
    February 14, 2012 | The Washington Examiner
  • The Sinews of Safety
    February 9, 2012 | The Burrill Report
  • Drug Supplies and Economics 101
    February 3, 2012 | The Burrill Report
  • Cutting Healthcare Spending with Occam's Razor
    January 13, 2012 | The Burrill Report
  • May 2009 | Nature Biotechnology
  • FDA On Warpath For Google Links
    May 2009 | Nature Biotechnology
Sign Up for Our Email Newsletter

RECENT NEWS

The coronavirus could help pharma reset its reputation in Washington

The coronavirus could help pharma reset its reputation in Washington

The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington....  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Tort bar’s newest collateral damage: Preterm babies

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers...  Read more

DRUGWONKS BLOG